Skip to main content

Using the Food and Drug Administration's Sentinel System for Surveillance of TB Infection

Basic Details
Date
Type
Publication
Description

We examined patterns in care for individuals treated for latent TB infection (LTBI) in the US Food and Drug Administration's Sentinel System.

Using administrative claims data, we identified patients who filled standard LTBI treatment prescriptions during 2008–2019. In these cohorts, we assessed LTBI testing, clinical management, and treatment duration.

 

Materials

Int. J. of Tuberculosis and Lung Dis. 2022 Dec 01. doi.org/10.5588/ijtld.22.0259

Related Assessment(s)
Sentinel Methods Report: Incidence of Latent Tuberculosis Infection: A Descriptive Analysis
Sentinel Drug Study: Latent Tuberculosis Infection & Surveillance
Author(s)

Kristine M. Schmit, William L. Walker, Emily C. Welch, Laura A. Vonnahme, Amish Talwar, Michael Nguyen, Danijela Stojanovic, Adam J. Langer, Noelle M. Cocoros

Corresponding Author

William L. Walker; Surveillance, Epidemiology, and Outbreak Investigations Branch, Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA.

Email: lxq4@cdc.gov